Brief: Solvonis Therapeutics Plans IND Submission For Phase 2B Trial Of SVN-2 In U.S.
Today 07:48
BRIEF-Solvonis Therapeutics Plans IND Submission For Phase 2B Trial Of SVN-2 In U.S. June 22 (Reuters) - Solvonis Therapeutics PLC SVNS.L:
SOLVONIS THERAPEUTICS - ANNOUNCES POSITIVE BRIDGING DATA FOR SVN-2 U.S. 505(B)(2) PATHWAY
SOLVONIS THERAPEUTICS - PLANS IND SUBMISSION FOR PHASE 2B TRIAL OF SVN-2 IN U.S.
Source text: ID:nRSV1056Ja
Further company coverage: SVNS.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Solvonis Therapeutics
See all newsBrief: Solvonis Therapeutics Plans IND Submission For Phase 2B Trial Of SVN-2 In U.S.
Solvonis Therapeutic - Announces Positive Bridging Data Supporting
Solvonis Therapeutic - Notice of Annual General Meeting
RCS - Solvonis Therapeutic - CSO Speaks at National Research Meeting
Solvonis Therapeutic - Final Results